Pacer Advisors, Inc. Cerevel Therapeutics Holdings, Inc. Transaction History

Pacer Advisors, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$38.96 - $42.75 $311 - $342	8 Added 0.77%	1,043 $42,000
Q1 2024 May 10, 2024	BUY	$40.88 - $43.27 $42,310 - $44,784	1,035 New	1,035 $43,000
Q2 2021 Jul 21, 2021	SELL	$12.56 - $29.69 $18,136 - $42,872	-1,444 Closed	0 $0
Q1 2021 Apr 05, 2021	BUY	$12.37 - $17.74 $17,862 - $25,616	1,444 New	1,444 $20,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.